Jul. 12 at 7:04 PM
$LEXX A successful Human Study #7 trial shifts Lexaria from a speculative micro-cap to a validated asset, triggering a multi-dollar structural re-rate across three waves:
Wave 1 (Overnight):
$3.25–
$4.00 (
$80M–
$100M mkt cap). Immediate gap up to align with oral delivery peer comps like
$RANI.
Wave 2 (Institutional):
$4.50–
$6.00 (
$110M–
$150M mkt cap). Analyst price target upgrades trigger buying from institutional funds finally cleared to own the stock.
Wave 3 (Buyout Speculation):
$8.00+ (
$200M+ mkt cap). The market begins pricing in a tier-1 pharma bidding war ahead of the Dec 31 exclusivity deadline.
A
$200M+ valuation remains an absolute steal for an acquirer when compared to Novo Nordisk's
$1.8B acquisition of the inferior SNAC carrier.
$RANI $IBB $XBI $IYH
